PURPOSE To update evidence-based guideline recommendations to practicing oncologists
and others on systemic therapy for patients with human epidermal growth factor receptor 2 …

Purpose To update evidence-based guideline recommendations for practicing oncologists
and others on systemic therapy for patients with human epidermal growth factor receptor 2 …

Purpose To provide evidence-based recommendations to practicing oncologists and others
on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2) …

Purpose To identify optimal chemo-and targeted therapy for women with human epidermal
growth factor 2 (HER2)–negative (or unknown) advanced breast cancer. Methods A …

Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

PURPOSE This guideline updates recommendations of the ASCO guideline on
chemotherapy and targeted therapy for patients with human epidermal growth factor …

Purpose Trastuzumab and pertuzumab are human epidermal growth factor receptor 2
(HER2)–targeted monoclonal antibodies, and trastuzumab emtansine (T-DM1) is an …

Purpose The efficacy of lapatinib versus trastuzumab combined with taxanes in the first-line
setting of human epidermal growth factor receptor 2 (HER2)–positive metastatic breast …

Near 75% of all breast cancers (BC) express estrogen receptors (ER) and/or progesterone
receptors (PgR), while up to 20% of BC show an overexpression/amplification of Human …

Purpose To evaluate the efficacy and safety of docetaxel, cisplatin, and trastuzumab as
primary systemic therapy for human epidermal growth factor receptor 2 (HER2)–positive …